Search

A study conducted at Nanjing Medical University in Jiangsu, China, explored the impact of combining high-flow nasal oxygen therapy (HFNO) with ipratropium bromide (IB) on patients with chronic obstructive pulmonary disease (COPD) and respiratory failure. The research involved 162 patients and found that the combined treatment was more effective in improving lung function, restoring Th1/Th2 balance, and reducing inflammation compared to HFNO alone. This study suggests that HFNO combined with IB may be beneficial for COPD patients with respiratory failure. [Extracted from the article]

A study conducted in Zhejiang, China, focused on the clinical efficacy of combining acetylcysteine with tiotropium bromide inhalation for acute exacerbations of chronic obstructive pulmonary disease (COPD). The research found that the combination therapy resulted in higher overall treatment efficacy, lower symptom scores, and improved pulmonary function and quality of life compared to tiotropium inhalation alone. Additionally, patients receiving the combination therapy exhibited lower levels of inflammatory factors and higher lung function parameters post-treatment. The study suggests that acetylcysteine combined with tiotropium bromide inhalation may be superior in treating patients with acute exacerbations of COPD. [Extracted from the article]

Researchers from Misr University for Science and Technology have developed three spectrophotometric methods for the simultaneous determination of the anticholinergic bronchodilators Ipratropium and Fenoterol in their combined inhaler dosage form. These methods are accurate, simple, cost-effective, and eco-friendly, using water as a green solvent. The methods were validated and found to be effective in assaying the co-formulated marketed inhaler and confirming dose uniformity. The research adheres to white analytical chemistry postulates and has been evaluated for its greenness and blueness. [Extracted from the article]

The article focuses on evaluating the impact of tiotropium/olodaterol combination therapy on respiratory dynamics in chronic obstructive pulmonary disease (COPD) using dynamic chest radiography (DCR). Topics include the use of DCR to assess changes in lung area and respiratory kinetics, the design of the study including its methodology and endpoints, and the expected outcomes of the research on respiratory function and patient-related outcomes.

This document provides information about a clinical trial for a drug called Spiriva Handihaler. The trial is currently active but not recruiting participants, with an enrollment of 186 people. The study aims to evaluate the pharmacokinetics and pharmacodynamics of Spiriva Handihaler compared to a test product called Tiotropium Bromide Inhalation Powder. The trial is being conducted in China and is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. [Extracted from the article]

A study conducted in Beijing, China, analyzed the efficacy and safety of a combination therapy for chronic obstructive pulmonary disease (COPD). The research group received salmeterol/fluticasone propionate plus tiotropium bromide therapy, while the control group received tiotropium bromide alone. The research found that the combination therapy had a higher overall response rate, improved pulmonary function, and lower levels of inflammatory markers compared to the control group. The study concluded that the combination therapy was effective and safe for treating COPD, with better outcomes in terms of pulmonary function, inflammatory markers, and quality of life. [Extracted from the article]

A new study published in the Biomedical and Pharmacology Journal explores the interaction between adenosine receptor blockers and anticholinergic substances in the treatment of bronchial asthma. The study aimed to assess changes in lung function parameters after administering ipratropium bromide alone and in combination with bamifylline. The results showed that the addition of anticholinergic substances did not enhance the effects of adenosine receptor blockers in patients with bronchial asthma. These findings suggest the need for further research to explore alternative therapeutic approaches in the management of bronchial asthma. [Extracted from the article]

A study conducted by researchers at Zhejiang Chinese Medical University in Hangzhou, China, explored the effects of combining tiotropium bromide, a bronchodilator, with traditional Chinese medicine (TCM) on patients with stable chronic obstructive pulmonary disease (COPD). The study involved 200 patients who were randomly assigned to either a trial group or a control group. The trial group received TCM granules in addition to tiotropium, while the control group received a placebo. The results showed that the TCM treatment effectively improved symptoms, lung function, and quality of life in stable COPD patients. The study suggests that TCM may have potential in the treatment of COPD. [Extracted from the article]

This document provides information about a clinical trial, NCT06376942, that is investigating the effectiveness of nebulized glycopyrrolate versus nebulized ipratropium in suppressing cough during flexible bronchoscopy. The researchers believe that nebulized glycopyrrolate will improve the procedure by reducing cough and improving patient comfort. The trial will measure outcomes such as cough count, airway secretion, cough intensity, patient comfort, and adverse reactions. The study is in Phase 2/Phase 3 and is expected to enroll 1050 participants, with an estimated completion date of June 15, 2025. The study is being conducted in India and the primary contact is Ritesh Agarwal. [Extracted from the article]

A recent report from Tehran University of Medical Sciences discusses the complications associated with hematopoietic stem cell transplant (HSCT), including graft-versus-host disease. The report focuses on bronchiolitis obliterans syndrome (BOS), a pulmonary form of this syndrome, and the lack of a standard treatment for it. The researchers are conducting a clinical trial to evaluate the efficacy of tiotropium bromide, a bronchodilator, in patients with BOS. The study is ongoing, and the findings will be disseminated through peer-reviewed publications, conferences, and seminars. [Extracted from the article]

This document provides information about a clinical trial conducted by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. The trial compares the effects of two different drugs, Spiriva HandiHaler and Tiotropium Bromide Inhalation Powder, for the treatment of respiratory conditions. The trial is currently active but not recruiting participants, with an estimated completion date of April 2024. The eligibility criteria for participants are outlined, including age, weight, and medical history. The document also includes administrative information such as study ID numbers and responsible parties. [Extracted from the article]

A patent application has been submitted for nebulization formulations for delivery to the lower respiratory tract. Respiratory tract conditions are common ailments that can cause obstructions and discomfort. The method involves mixing dry powder ingredients to formulate a dry powder mixture, which can then be enclosed in a capsule or other pharmaceutical container. The dry powder can include beta agonists, anticholinergics, mucolytics, and other active and inactive ingredients. The method also includes combining the dry powder with a sterile diluent and nebulizing the solution or suspension to generate particles for delivery to the lower respiratory tract. [Extracted from the article]

Researchers from the University of Antioquia have conducted a study on the cost-effectiveness of tiotropium as an add-on therapy for patients with severe asthma. The study found that tiotropium was cost-effective when added to usual care for patients who remained uncontrolled despite treatment with inhaled corticosteroids and long-acting bronchodilators. The findings suggest that tiotropium could be a valuable addition to clinical practice guidelines and should be further validated in other middle-income countries. The study was published in the journal Cost Effectiveness and Resource Allocation. [Extracted from the article]

A study conducted by Baylor University College of Medicine compared the use of tiotropium bromide (Tio) and long-acting beta 2-agonists (LABA) as add-ons to inhaled corticosteroids (ICS) for the treatment of uncontrolled asthma. The study found that there was no significant difference in the proportion of patients who experienced severe or moderate-to-severe exacerbations between the two treatment groups. However, healthcare resource utilization was higher in the ICS + Tio group for asthma-related outpatient visits. The study suggests that ICS + Tio may be a valid alternative when ICS/LABA cannot be used as first-line treatment for asthma maintenance therapy. [Extracted from the article]

A recent study conducted by the University of Oklahoma Health Sciences Center College of Pharmacy has found that multidose inhalers of tiotropium, an anticholinergic bronchodilator, often result in wasted doses when dispensed to hospitalized patients. The study compared the wastage of multidose tiotropium packages to single-use revefenacin vials, a nebulized alternative. The researchers discovered that approximately $24,000 worth of tiotropium doses were wasted, highlighting the potential for minimizing wastage and cost savings by using nebulized vials instead. This study provides valuable insights for hospital and health-system pharmacies in their decision-making processes. [Extracted from the article]

Keywords: Valparaiso; Chile; South America; Antiasthmatic Agents; Anticholinergic Bronchodilators; Antimuscarinic; Antispasmodics; Atropine Derivatives; Aza Compounds; Azabicyclo Compounds; Bronchodilators; Cholinergic Antagonist; Controlled Release; Cromolyn Therapy; Drug Delivery; Drug Delivery Systems; Drugs and Therapies; Gelatin; Health and Medicine; Ipratropium; Ipratropium Therapy; Mast Cell Stabilizers; Pharmaceuticals; Proteins; Respiratory Agents; Respiratory Inhalant Products; Scleroproteins; Tropanes EN Valparaiso Chile South America Antiasthmatic Agents Anticholinergic Bronchodilators Antimuscarinic Antispasmodics Atropine Derivatives Aza Compounds Azabicyclo Compounds Bronchodilators Cholinergic Antagonist Controlled Release Cromolyn Therapy Drug Delivery Drug Delivery Systems Drugs and Therapies Gelatin Health and Medicine Ipratropium Ipratropium Therapy Mast Cell Stabilizers Pharmaceuticals Proteins Respiratory Agents Respiratory Inhalant Products Scleroproteins Tropanes 3173 3173 1 11/06/23 20231110 NES 231110 2023 NOV 10 (NewsRx) -- By a News Reporter-Staff News Editor at Respiratory Therapeutics Week -- Investigators discuss new findings in Drugs and Therapies - Anticholinergic Bronchodilators. Ionized cromoglicate sodium (CS) and ipratropium bromide (IBr) interacted in solution with charged gelatin before spray drying (SD). [Extracted from the article]

For more information on this research see: Clinical and Economic Outcomes In Patients With Chronic Obstructive Pulmonary Disease Initiating Maintenance Therapy With Tiotropium Bromide/olodaterol or Fluticasone Furoate/umeclidinium/vilanterol. Keywords: Ridgefield; State:Connecticut; United States; North and Central America; Adrenergic beta2-Agonists; Animal Health Companies; Anticholinergic Bronchodilators; Biopharmaceutical Companies; Business; Chronic Obstructive Pulmonary Disease; Dermatological Agents; Drugs and Therapies; Fluticasone Furoate; Fluticasone Therapy; Health and Medicine; Healthcare Biotechnology Companies; Infectious Disease; Inhaled Corticosteroids; Lung Diseases and Conditions; Nasal Steroids; Pharmaceuticals; Pneumonia; Pulmonary Disease; Pulmonology; Respiratory Agents; Respiratory Inhalant Products; Respiratory Tract Diseases and Conditions; Respiratory Tract Infections; Risk and Prevention; Tiotropium Therapy; Topical Steroids EN Ridgefield State:Connecticut United States North and Central America Adrenergic beta2-Agonists Animal Health Companies Anticholinergic Bronchodilators Biopharmaceutical Companies Business Chronic Obstructive Pulmonary Disease Dermatological Agents Drugs and Therapies Fluticasone Furoate Fluticasone Therapy Health and Medicine Healthcare Biotechnology Companies Infectious Disease Inhaled Corticosteroids Lung Diseases and Conditions Nasal Steroids Pharmaceuticals Pneumonia Pulmonary Disease Pulmonology Respiratory Agents Respiratory Inhalant Products Respiratory Tract Diseases and Conditions Respiratory Tract Infections Risk and Prevention Tiotropium Therapy Topical Steroids 1544 1544 1 09/11/23 20230911 NES 230911 2023 SEP 15 (NewsRx) -- By a News Reporter-Staff News Editor at Veterinary Week -- Fresh data on Lung Diseases and Conditions - Chronic Obstructive Pulmonary Disease are presented in a new report. [Extracted from the article]

Keywords: Anticholinergic Bronchodilators; Asthma; Bronchial Diseases and Conditions; Drugs and Therapies; Health and Medicine; Immune System Diseases and Conditions; Lung Diseases and Conditions; Obstructive Lung Diseases and Conditions; Pediatrics; Pharmaceuticals; Respiratory Agents; Respiratory Hypersensitivity; Respiratory Tract Diseases and Conditions; Tiotropium Therapy EN Anticholinergic Bronchodilators Asthma Bronchial Diseases and Conditions Drugs and Therapies Health and Medicine Immune System Diseases and Conditions Lung Diseases and Conditions Obstructive Lung Diseases and Conditions Pediatrics Pharmaceuticals Respiratory Agents Respiratory Hypersensitivity Respiratory Tract Diseases and Conditions Tiotropium Therapy 2423 2423 1 08/14/23 20230818 NES 230818 2023 AUG 18 (NewsRx) -- By a News Reporter-Staff News Editor at Respiratory Therapeutics Week -- Investigators publish new report on asthma. Anticholinergic Bronchodilators, Asthma, Bronchial Diseases and Conditions, Drugs and Therapies, Health and Medicine, Immune System Diseases and Conditions, Lung Diseases and Conditions, Obstructive Lung Diseases and Conditions, Pediatrics, Pharmaceuticals, Respiratory Agents, Respiratory Hypersensitivity, Respiratory Tract Diseases and Conditions, Tiotropium Therapy. [Extracted from the article]

For more information on this research see: Preoperative Umeclidinium/vilanterol or Tiotropium Improves Postoperative Fev1 In Lung Cancer Patients With Comorbid Untreated Chronic Obstructive Pulmonary Disease. Keywords: Toyama; Japan; Asia; Anticholinergic Bronchodilators; Cancer; Chronic Obstructive Pulmonary Disease; Drugs and Therapies; Health and Medicine; Lung Cancer; Lung Diseases and Conditions; Lung Neoplasms; Oncology; Pharmaceuticals; Pulmonary Disease; Respiratory Agents; Tiotropium Therapy EN Toyama Japan Asia Anticholinergic Bronchodilators Cancer Chronic Obstructive Pulmonary Disease Drugs and Therapies Health and Medicine Lung Cancer Lung Diseases and Conditions Lung Neoplasms Oncology Pharmaceuticals Pulmonary Disease Respiratory Agents Tiotropium Therapy 269 269 1 05/15/23 20230519 NES 230519 2023 MAY 16 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Researchers detail new data in Lung Diseases and Conditions - Chronic Obstructive Pulmonary Disease. [Extracted from the article]

For more information on this research see: Effect of topical anticholinergic medication on clinical manifestations control among patients with vasomotor rhinitis versus allergic rhinitis: as comparative clinical trials. Keywords: Allergic Rhinitis; Allergies; Allergy Research; Anticholinergic Bronchodilators; Antimuscarinic; Antispasmodics; Bronchodilators; Cholinergic Antagonist; Clinical Research; Clinical Trials and Studies; Cosmetic Techniques; Drugs and Therapies; Health and Medicine; Immune System Diseases and Conditions; Ipratropium Therapy; Nose Diseases and Conditions; Otorhinolaryngologic Diseases and Conditions; Pharmaceuticals; Respiratory Agents; Respiratory Tract Diseases and Conditions; Respiratory Tract Infections; Rhinitis; Rhinoplasty; Risk and Prevention; Vasomotor Rhinitis EN Allergic Rhinitis Allergies Allergy Research Anticholinergic Bronchodilators Antimuscarinic Antispasmodics Bronchodilators Cholinergic Antagonist Clinical Research Clinical Trials and Studies Cosmetic Techniques Drugs and Therapies Health and Medicine Immune System Diseases and Conditions Ipratropium Therapy Nose Diseases and Conditions Otorhinolaryngologic Diseases and Conditions Pharmaceuticals Respiratory Agents Respiratory Tract Diseases and Conditions Respiratory Tract Infections Rhinitis Rhinoplasty Risk and Prevention Vasomotor Rhinitis 1017 1017 1 04/10/23 20230414 NES 230414 2023 APR 10 (NewsRx) -- By a News Reporter-Staff News Editor at Respiratory Therapeutics Week -- Investigators discuss new findings in vasomotor rhinitis. [Extracted from the article]

Keywords: Bergen; Norway; Europe; Anticholinergic Bronchodilators; Antimuscarinic; Antispasmodics; Atropine Derivatives; Aza Compounds; Azabicyclo Compounds; Bronchodilators; Cholinergic Antagonist; Drugs and Therapies; Health and Medicine; Ipratropium; Ipratropium Therapy; Pharmaceuticals; Respiratory Agents; Tropanes EN Bergen Norway Europe Anticholinergic Bronchodilators Antimuscarinic Antispasmodics Atropine Derivatives Aza Compounds Azabicyclo Compounds Bronchodilators Cholinergic Antagonist Drugs and Therapies Health and Medicine Ipratropium Ipratropium Therapy Pharmaceuticals Respiratory Agents Tropanes 1633 1633 1 03/23/23 20230310 NES 230310 2023 MAR 10 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- New research on Drugs and Therapies - Anticholinergic Bronchodilators is the subject of a report. Bergen, Norway, Europe, Anticholinergic Bronchodilators, Antimuscarinic, Antispasmodics, Atropine Derivatives, Aza Compounds, Azabicyclo Compounds, Bronchodilators, Cholinergic Antagonist, Drugs and Therapies, Health and Medicine, Ipratropium, Ipratropium Therapy, Pharmaceuticals, Respiratory Agents, Tropanes. [Extracted from the article]